Clinical Trials at University of Michigan Comprehensive Cancer Center
As of July 2026, 29 paid clinical trials are recruiting at University of Michigan Comprehensive Cancer Center, located at 328 THOMPSON ST, SUITE 2, ANN ARBOR, MI 48104-2264, phone (734) 276-2496 in Ann Arbor, Michigan. Active studies at this site cover conditions such as Advanced Solid Tumor, Obesity and Prostate Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
29 clinical trials at University of Michigan Comprehensive Cancer Center
·Clear filters·A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Gilteritinib for the Treatment of ALK NSCLC
Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Common conditions studied in Ann Arbor
- Advanced Solid Tumor (10 active studies)
- Obesity (10 active studies)
- Prostate Cancer (10 active studies)
- Colorectal Cancer (9 active studies)
- Malignant Solid Neoplasm (9 active studies)
- Stroke (9 active studies)
Leading research sponsors in Ann Arbor
- University of Michigan
- University of Michigan Rogel Cancer Center
- National Cancer Institute (NCI)
- VA Office of Research and Development
- Children's Oncology Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Ann Arbor?
There are approximately 978 recruiting clinical trials in Ann Arbor, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Ann Arbor pay participants?
Most recruiting trials in Ann Arbor compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Ann Arbor?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Ann Arbor?
The most common conditions under active study in Ann Arbor include Advanced Solid Tumor (10), Obesity (10), Prostate Cancer (10), Colorectal Cancer (9), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Ann Arbor?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Ann Arbor on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Ann Arbor?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Ann Arbor?
Recruiting research sites in Ann Arbor include University of Michigan, University of Michigan Rogel Cancer Center, Trinity Health Saint Joseph Mercy Hospital Ann Arbor, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Ann Arbor right now?
The largest active categories in Ann Arbor are Cancer & tumors (287), Neurology & pain (77), Cardiovascular (56). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of Michigan Comprehensive Cancer Center?
University of Michigan Comprehensive Cancer Center is located at 328 THOMPSON ST, SUITE 2, ANN ARBOR, MI 48104-2264. Use the Google Maps link in the intro above to get directions.
How do I contact University of Michigan Comprehensive Cancer Center?
You can reach University of Michigan Comprehensive Cancer Center by phone at (734) 276-2496. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.